Having trouble accessing articles? Reset your cache.

Genmab's Arzerra misses in Phase III for indolent NHL

Genmab A/S (CSE:GEN) said Arzerra ofatumumab plus Treanda bendamustine missed the primary endpoint of improving progression-free

Read the full 160 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE